Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
753.03
+3.52 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
42
43
Next >
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
May 31, 2022
The U.S.
Via
Benzinga
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
May 30, 2022
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data...
Via
Benzinga
United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds
May 28, 2022
United Airlines headlines five stocks to watch for the week ahead.
Via
Investor's Business Daily
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
May 23, 2022
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
How Regeneron Pharmaceuticals Beat Quarterly Projections Without Leaning On Covid
May 04, 2022
Excluding the company's Covid antibody, sales surged 25% and still topped forecasts.
Via
Investor's Business Daily
Here's Why This Analyst Cut Price Target On Regeneron
May 02, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
May 23, 2022
Via
Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
May 20, 2022
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.
Via
Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
May 19, 2022
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?
Via
Investor's Business Daily
Gilead Stock Earns Rating Upgrade After Quick Turnaround
May 19, 2022
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?
Via
Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
May 16, 2022
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between...
Via
Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
May 13, 2022
The race is on in eczema treatment as the biggest name faces new rivals.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
May 11, 2022
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.
Via
Investor's Business Daily
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
May 06, 2022
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020.
Via
Investor's Business Daily
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
May 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
May 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Preview: Regeneron Pharmaceuticals
May 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
May 02, 2022
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest
April 25, 2022
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 6.48% since its last report. The company recently reported that it has 2.39 million shares sold...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
April 21, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron...
Via
Benzinga
54 Biggest Movers From Yesterday
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
April 19, 2022
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it.
Via
InvestorPlace
38 Stocks Moving In Tuesday's Mid-Day Session
April 19, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...
Via
Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
April 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.